Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)

被引：6
|
作者：
Janne, P. A. [1 ]
Wu, Y-L. [2 ,3 ]
Kato, T. [4 ]
Besse, B. [5 ]
Peters, S. [6 ]
Nguyen, D. [7 ]
Berg, D. [8 ]
Lin, J. [9 ]
Feng, Z. [10 ]
Mok, T. [11 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Kanagawa Canc Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[5] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[6] Ctr Hosp Univ Vaudois CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
[7] Pacific Shores Med Grp, Hematol & Oncol, Long Beach, CA USA
[8] Millennium Pharmaceut Inc, Oncol Clin Res & Dev, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Stat, Cambridge, MA USA
[10] Millennium Pharmaceut Inc, Clin Sci, Cambridge, MA USA
[11] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1412TiP
引用
收藏
页码：S892 / S893
页数：2
相关论文
共 50 条
  • [21] Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
    Horn, Leora
    Lin, Huamao Mark
    Padda, Sukhmani Kaur
    Aggarwal, Charu
    McCoach, Caroline Elizabeth
    Zhu, Yanyan
    Yin, Yu
    Lin, Jianchang
    Li, Shuanglian
    Feng, Zhongling
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer
    Yang, James Chih-Hsin
    Zhou, Caicun
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Kim, Tae Min
    Riely, Gregory J.
    Spira, Alexander, I
    Piotrowska, Zofia
    Mekhail, Tarek
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Bazhenova, Lyudmila
    Jin, Shu
    Kaur, Manmit
    Diderichsen, Paul M.
    Gupta, Neeraj
    Bunn, Veronica
    Lin, Jianchang
    Churchill, Eric
    Mehta, Minal
    Nguyen, Danny
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 95 - 106
  • [23] Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
    Yang, J. C-H.
    Wang, M.
    Chiu, C-H.
    Hsu, P-C.
    Mitchell, P.
    Chang, C. L.
    Kim, T. M.
    John, T.
    Greillier, L.
    Bazhenova, L.
    Carcereny, E.
    Spira, A. I.
    Shim, B.
    Lee, K. H.
    Cobo Dols, M.
    Ghiringhelli, F.
    Yip, C. W.
    Xiong, J.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
    Spira, Alexander
    Waters, Dexter
    Ran, Tao
    Vadagam, Pratyusha
    He, Jinghua
    Vanderpoel, Julie
    Donnelly, Anjali
    Lin, Iris
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [25] Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
    Imran, Mohd
    Khan, Shah Alam
    Alshammari, Mohammed Kanan
    Alreshidi, Meshal Ayedh
    Alreshidi, Abeer Abdullah
    Alghonaim, Rawan Sulaiman
    Alanazi, Fayez Aboud
    Alshehri, Sultan
    Ghoneim, Mohammed M.
    Shakeel, Faiyaz
    BIOMEDICINES, 2021, 9 (12)
  • [26] The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
    Kaakour, Dalia
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 49 - 54
  • [27] EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/ metastatic NSCLC
    Janne, P. A.
    Wang, B-C.
    Cho, B. C.
    Zhao, J.
    Li, J.
    Hochmair, M. J.
    Peters, S.
    Besse, B.
    Kato, T.
    Wu, Y-L.
    Nguyen, D.
    Lin, J.
    Lin, J.
    Vranceanu, F.
    Lin, M.
    Fram, R. J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1663 - S1664
  • [28] Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison
    Ou, Sai -Hong Ignatius
    Prawitz, Thibaud
    Lin, Huamao M.
    Hong, Jin-liern
    Tan, Min
    Proskorovsky, Irina
    Hernandez, Luis
    Jin, Shu
    Zhang, Pingkuan
    Lin, Jianchang
    Patel, Jyoti
    Nguyen, Danny
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2024, 25 (03) : e145 - e152.e3
  • [29] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Bunn, Veronica
    Jin, Shu
    Zhou, Caicun
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC
    Lu, S.
    Zhou, C.
    Cho, B. C.
    Ono, A.
    Hayashi, H.
    Majem, M.
    Lee, S-H.
    Richardson, G.
    Sabari, J. K.
    Girard, N.
    Sanborn, R. E.
    Mansfield, A. S.
    Buyukkaramikli, N.
    Perualila, N.
    Acharya, S.
    Chandler, C.
    Dearden, L.
    Agrawal, T.
    Baig, M.
    Park, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1638 - S1639
12345